Dr. Jonathan Burbaum currently serves as the sole Principal of Gnosys, Inc., a company based in San Francisco. He is also a venture partner with Innovating Capital, an early-stage venture fund. He formerly held a similar position with Genoa Ventures and was an EIR with Spruce Capital Partners.
Gnosys provides life science business development and technology consulting. The company has had clients that include venture-backed startups, a Fortune 50 company, and venture firms.
Prior to moving to the Bay Area, Jonathan was a Program Director at the Advanced Research Projects Agency-Energy (ARPA-E), focusing broadly on transportation energy, from advanced biotechnology applications for biofuels to network optimization applied to personal transportation energy use. He has had a long career as a technology leader, primarily focusing on realizing value from novel technologies, products, and commercial strategies in the life sciences. He founded a San Diego-based company, Azure Therapeutics, and has worked extensively for corporate, venture, and government clients. He has also played seminal roles with two venture-backed startup companies, Pharmacopeia (Princeton, NJ) from inception, through IPO and commercial launch, and as VP of Research for ActivX Biosciences (San Diego, CA). He began his industrial career at the Merck Research Laboratories in 1991.
Jonathan received his B.S. in Chemistry from Rensselaer Polytechnic Institute in 1981, and his Ph. D. from Harvard University – where he worked for Jeremy R. Knowles on the energetics of enzymatic catalysis – in 1988. From 1988 to 1991, Jonathan conducted post-doctoral work at the Massachusetts Institute of Technology with Paul Schimmel, focusing on protein structure, function and folding. He received his M.B.A. from the Rady School of Management at the University of California, San Diego in 2009.